Log In
Print
BCIQ
Print
Print this Print this
 

Gardasil, Silgard

  Manage Alerts
Collapse Summary General Information
Company Merck & Co. Inc.
DescriptionHPV types 6, 11, 16 and 18 recombinant vaccine
Molecular Target Not applicable
Mechanism of ActionVaccine
Therapeutic ModalityPreventive vaccine: DNA vaccine
Latest Stage of DevelopmentMarketed
Standard IndicationHuman papillomavirus (HPV)
Indication DetailsDetermine the prevalence of human papillomavirus (HPV) infection among females in the U.S.; Prevent anal intraepithelial neoplasia (AIN) and anal cancer associated with HPV types 6, 11, 16 and 18 in men and women ages 9-26; Prevent anal intraepithelial neoplasia (AIN) associated with HPV types 6, 11, 16 and 18 in men ages 16-26; Prevent cervical cancer, vulvar and vaginal cancers, precancerous lesions and genital warts caused by HPV types 6, 11, 16 and 18 in women ages 9-45; Prevent external genital lesions caused by HPV in males; Prevent genital warts caused by human papillomavirus (HPV); Prevent HPV infection; Prevent HPV-related anal dysplasia and anal cancer; Prevent human papillomavirus (HPV) types 6, 11, 16 and 18-related persistent infection, cervical and genital disease in women ages 24-45; Prevent premalignant genital lesions, premalignant anal lesions, cervical cancers and anal cancers causally related to certain oncogenic HPV types and genital warts causally related to specific HPV types in people ages >=9 years; To prevent cervical cancer and its precancerous lesions, vulvar and vaginal precancerous lesions and genital warts caused by HPV types 6, 11, 16 and 18 in females 9 years of age and older
Regulatory Designation

Partner

Sanofi


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today